Axon Enterprise (NASDAQ:AXON) CAO Jennifer Mak Sells 1,134 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) CAO Jennifer Mak sold 1,134 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $600.00, for a total value of $680,400.00. Following the completion of the transaction, the chief accounting officer owned 13,740 shares of the company’s stock, valued at $8,244,000. This trade represents a 7.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Axon Enterprise Price Performance

NASDAQ AXON opened at $591.02 on Wednesday. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91. The company has a market cap of $46.64 billion, a PE ratio of 187.03, a PEG ratio of 137.85 and a beta of 1.40. The stock’s 50-day moving average price is $603.75 and its two-hundred day moving average price is $704.42.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. During the same period last year, the business earned $1.45 earnings per share. The business’s revenue was up 30.6% on a year-over-year basis. On average, analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allworth Financial LP lifted its holdings in shares of Axon Enterprise by 1.0% during the 3rd quarter. Allworth Financial LP now owns 5,792 shares of the biotechnology company’s stock valued at $4,156,000 after buying an additional 58 shares during the last quarter. Swiss Life Asset Management Ltd raised its position in Axon Enterprise by 23.5% during the third quarter. Swiss Life Asset Management Ltd now owns 14,153 shares of the biotechnology company’s stock valued at $10,157,000 after acquiring an additional 2,694 shares in the last quarter. Strategic Advocates LLC lifted its stake in Axon Enterprise by 1.2% in the third quarter. Strategic Advocates LLC now owns 1,856 shares of the biotechnology company’s stock valued at $1,332,000 after acquiring an additional 22 shares during the last quarter. CIBC Private Wealth Group LLC lifted its stake in Axon Enterprise by 26.4% in the third quarter. CIBC Private Wealth Group LLC now owns 186,538 shares of the biotechnology company’s stock valued at $133,867,000 after acquiring an additional 38,966 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Axon Enterprise in the third quarter worth approximately $9,718,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AXON shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $870.00 target price on shares of Axon Enterprise in a research report on Wednesday, September 24th. Morgan Stanley reduced their price objective on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. The Goldman Sachs Group dropped their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Piper Sandler reduced their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.71.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.